David OMalley
@omalleygynonc
Followers
689
Following
12
Media
21
Statuses
232
Joined March 2014
What is the impact of the PICCOLO trial? Is this a new option for our patients? A start to understanding a unique patient population? Does it ask more questions than answers? .
0
0
1
Amazing collaboration, update on KEYNOTE-158 endometrial MMRd cohorts. Changing the dialogue, we can cure patients with metastatic/recurrent uterine cancer. HIGHLIGHTS: ORR 50% in dMMR; 66% 4-yr DOR estimated.
0
0
2
Join us live or in Washington, DC, later this month for a unique NCPD hybrid symposium series. Visit our website for more information and registration. Additional sessions to be announced.
0
0
1
RT @DrNeilLove: Join us live or in Washington, DC, later this month for a unique NCPD hybrid symposium series. Visit our website for more i….
0
1
0
Curative intent should be the goal for patients with recurrent, persistent, metastatic cervical cancer. The best therapies need to be given in the first line. 30+% patient have not recurred at 3 years versus about 10%. @GOG @OSUCCC_James.
#ASCO2023 final OS of Keynote-826 confirming survival advantage of pembrolizumab in persistent,recurrent, metastatic cervical cancer. A one year improvement in median OS…and the tail of the curve is provocative!
0
0
4
A comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, with a focus on the use of PARPis as maintenance therapy. Changing times in PARPi!.
1
6
13
Just registered for my 15th year. ONE GOAL!!!!. Pelotonia is a community that is determined to save lives through funding innovative cancer research. Help us save more by donating today! #Pelotonia.
pelotonia.org
Pelotonia is a community that is determined to see an end to cancer. Together, we've saved countless lives. Help us save more.
0
0
3
Thanks to @CancerNetwrk for helping educate- Overview of Endometrial Carcinoma @gyncsm @OSUCCC_James .via @@CancerNetwrk.
cancernetwork.com
David O’Malley, MD, provides a comprehensive overview of endometrial carcinoma and treatment options for patients in this setting.
1
3
13
Thanks to @CancerNetwrk for helping educate about Molecular Profiling and Risk Stratification in Advanced Endometrial Carcinoma @OSUCCC_James @gyncsm ://www.cancernetwork.com/view/molecular-profiling-and-risk-stratification-in-advanced-endometrial-carcinoma via @@CancerNetwrk.
0
0
3
The premier paper on eye toxicity of Mirv written for non-ophthalmologist. A must read!.@OSUCCC_James .
0
0
5
Hoping to see many of our nursing colleagues at ONS for RTP @DrNeilLove discussion on ovarian cancer @OSUCCC_James #ONSCongress @GOG.
Check out our exciting lineup of NCPD hybrid events held in conjunction with the 48th Annual ONS Congress in April and keep an eye out for additional sessions to be added in the coming weeks. Register below. #ONSCongress.
0
0
3
Very low % Serous carcinomas in early stage trials: ACTION (35%), ICON1 (30%), GOG 157 (23%). Underestimating the recurrence rate????.
0
2
6
3 gBRCA & 1sBRCA received PARPi for upfront maintenance median F/u 39 months (31–47m) of follow-up, 0/4 cases have developed recurrence.
0
0
2
High (37%) rate of recurrences in HRD group, could indicate that tumor genetic status is important prognostic information in early-stage EOC. Upfront main strategy in an early-stage HRD population should be considered for future study.
0
2
17
CDK4/6i + AI exciting results in #lowgradeovariancancer. Most patients had disease regression. Tomorrow therapies today @GOG & @OSUCCC_James.
@GynCancerMD opening plenary at @SGO2023mtg Ribociclib and letrozole active in low grade serous #ovariancancer. Congrats! @SGO_org @GOG @gyncsm @SHAREing @IGCSociety
0
0
2
Patients on clinical trials have better survival than those on standard of care. Congrats to molly Morton and @LAURAJMOULTON @OSUCCC_James @ClevelandClinic @osugynonc
0
0
5
1 of @OSUCCC_James star fellows presenting how participation in clinical trials improve overall survival in platinum resistant ovarian cancer patients @GOG @SGO_org @gyncsm #SGOMtg.
Patients on clinical trials have better survival than those on standard of care. Congrats to molly Morton and @LAURAJMOULTON @OSUCCC_James @ClevelandClinic @osugynonc
0
3
15
AddThis | Home .Now part of NCCN guidelines for PROC. Earlier opportunity to gain access for patients in patients with PSOC (GOG 3078; GLORIOSA). @OSUCCC_James @GOG.
0
1
3
AddThis | Home .Now part of NCCN guidelines for PROC. Earlier opportunity to gain access for patients in patients with PSOC (GOG 3078; GLORIOSA). @OSUCCC_James @GOG.
0
4
9